NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE (potassium phosphates) by Fresenius Kabi is tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization. First approved in 2019.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Potassium phosphates in 0.9% sodium chloride is an intravenous electrolyte replacement solution administered to correct phosphate and potassium deficiencies in hospitalized patients. It works by replenishing essential minerals critical for nucleic acid synthesis, energy metabolism, cell signaling, and bone mineralization. This is a hospital-based critical care product with no oral alternative equivalent.
Peak15.4 years to LOE
Peak-stage hospital IV product with stable demand driven by critical care utilization; team size likely stable with focus on hospital formulary management and supply chain.
Mechanism of Action
tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this product positions you in the stable, high-stakes hospital critical care market where execution excellence and relationship management drive success. Career growth comes through deepening hospital formulary relationships, managing reimbursement complexity, and optimizing supply chain for a peak-stage IV product with strong patent protection.
Hospital Account Manager
Worked on POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.